Abstract
<span lang="EN-US">It is necessary to play a leading and exemplary role in the implementation of Chinese innovative development strategy, because of the economic, social and political status of state-owned pharmaceutical enterprises. Based on describing pharmaceutical ownership reforming and innovation status, the paper analyzed the dynamic innovation performance of the State-owned pharmaceutical enterprises by the Malmquist index of DEA (Data Envelopment Analysis), and result shows that the biological product field of state-owned enterprises obtained better innovation performance. Then the paper discussed the innovation performance of state-owned pharmaceutical enterprises by the empirical analysis of Panel data model, the results showed that the state-owned enterprise have the serious status of R&amp;D resource concentrating and excessing, but it is still achieve major force of Chinese pharmaceutical economic growth based on innovative activities. At last, the paper offered the upgrading road of state-owned enterprises innovation capability, such as the market radiating and integrating, micro-cooperation, organizational restructuring, and cross-regional integration.</span>
Highlights
In the third plenary session of 18th Communist Party of China (CPC) congress clearly put forward to the reform of the state-owned enterprise operation and management mode, get rid of the monopoly of the past, manage assets mainly to regulatory capital mainly to strengthen the state-owned capital supervision; especially state-owned enterprises take the mixed ownership reform mode, will stimulate the capital vitality of China, driven by the investment operation of social capital in a broader field which the industry gradually break the monopoly
The paper discussed the innovation performance of state-owned pharmaceutical enterprises by the empirical analysis of Panel data model, the results showed that the state-owned enterprise have the serious status of R&D resource concentrating and excessing, but it is still achieve major force of Chinese pharmaceutical economic growth based on innovative activities
The empirical analysis of the Panel Data model of pharmaceutical enterprises' profit and the related factors of industry innovation activity shows that there are some correlation between ownership structure type enterprises and innovation activities
Summary
In the third plenary session of 18th Communist Party of China (CPC) congress clearly put forward to the reform of the state-owned enterprise operation and management mode, get rid of the monopoly of the past, manage assets mainly to regulatory capital mainly to strengthen the state-owned capital supervision; especially state-owned enterprises take the mixed ownership reform mode, will stimulate the capital vitality of China, driven by the investment operation of social capital in a broader field which the industry gradually break the monopoly. In September 2015 the central government issued "on the promotion of state-owned cultural enterprises in putting social benefits first, to achieve social and economic benefits of the unity of guidance", the state-owned enterprises have the function to achieve the integration of economic responsibility, political responsibility and social responsibility. Analyzing the innovation behavior of state-owned enterprises under the background of the ownership structure reforming will give a better play to the positive role of the state-owned pharmaceutical enterprises in the implementation of national innovation and development strategy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
